Edgen Stock·Nov 24 2025, 13:01返回
返回
诺和诺德口服索马鲁肽在阿尔茨海默病试验中失败，股价下跌10%
Edgen Stock·Nov 24 2025, 13:01
[1] 诺和诺德称阿尔茨海默病药物试验未能达到主要目标 (https://www.reuters.com/business/healthcare-p ...)[2] 诺和诺德股价暴跌，因Ozempic口服药在阿尔茨海默病试验中失败... (https://www.wsj.com/health/pharma/novo-nordis ...)[3] 诺和诺德称阿尔茨海默病药物试验失败，股价受重创 (https://www.investing.com/news/stock-market-n ...)